Loading
INV-9956 is an experimental CYP11A1 inhibitor from Shenzhen Ionova Life Sciences, in phase 2 trials for metastatic castration-resistant prostate cancer.
INV-9956 is a CYP11A1 inhibitor from Shenzhen Ionova Life Sciences. A CYP11A1 inhibitor for castration-resistant prostate cancer, given with dexamethasone and fludrocortisone acetate in the trial. Its furthest stage is phase 2, for metastatic castration-resistant prostate cancer. ClinicalTrials.gov registers it in one study linked below. Company announced first patient dosed in the phase II trial (news dated 2025-12-05); FDA Fast Track for advanced mCRPC (news dated 2025-11-03). Registry trial is phase 1/2, recruiting. Whether it works in people has not been established unless a trial below reports it.
A CYP11A1 inhibitor for castration-resistant prostate cancer, given with dexamethasone and fludrocortisone acetate in the trial. Connects to CYP11A1 (cholesterol side-chain cleavage enzyme).
1.INV-9956 slips into a pocket on CYP11A1 (cholesterol side-chain cleavage enzyme).
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"INV-9956" OR ABSTRACT:"INV-9956") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about INV-9956, not a curated reading list.
Shares CYP11A1 (cholesterol side-chain cleavage enzyme), Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Shenzhen Ionova Life Sciences and the tag pipeline.
Shares Shenzhen Ionova Life Sciences and the tag pipeline.
Shares Shenzhen Ionova Life Sciences and the tag pipeline.
Shares Shenzhen Ionova Life Sciences and the tag pipeline.
Shares Shenzhen Ionova Life Sciences and the tag pipeline.
Shares Shenzhen Ionova Life Sciences and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/